Opzelura Experience Study
ConditionAtopic Dermatitis
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age2+
SponsorWake Forest University Health Sciences
About this trial
Atopic dermatitis is a common multifactorial skin disease. Topicals are the mainstay of treatment, but adherence to topicals is often abysmal, possibly worsened by the complexity of recommended treatment algorithms. Giving patients a simple, one drug approach may be advantageous.
Eligibility criteria
Qualifiers
Patients ≥2 years of age
Patients with a current diagnosis of atopic dermatitis that is mild-to-moderate in severity and in ≥2 body areas
Patients with up to 20% total body surface area involvement
Women of childbearing age taking/using a contraceptive
Disqualifiers
Patients without a current diagnosis of atopic dermatitis
Patients who are prescribed changing systemic medications or treatments (phototherapy, biologics) for atopic dermatitis
Patients who would require use of other topical medications for other diagnoses (tretinoin, clindamycin)
Patients with areas of skin with active infection
Trial design
Treatments tested in this trial
- ruxolitinib
- ruxolitinib and an Eczema Action Plan
Treatment groups
50 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov